Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
A 2026 review study explores nanocarriers, host-directed therapies, and antimicrobial peptides as next-generation tuberculosis treatments. Learn what the research shows.
By Peptide Association Research Team
New research explores nanocarriers, antimicrobial peptides, and host-directed strategies as next-generation tuberculosis treatments. Learn what the science says.
By Peptide Association Research Team
New zebrafish research suggests GHK-Cu peptide may reduce inflammation and oxidative stress. Learn what the study found and what it means for future research.
By Peptide Association Research Team
New research suggests elamipretide (SS-31) may support recovery after spinal cord injury by protecting mitochondria and reducing cell death. Learn what the study found.
By Peptide Association Research Team
New research explores carbonless analogues of the GHK peptide using boron-nitrogen substitution. Learn what this computational study suggests about future peptide design.
By Peptide Association Research Team
New computational research explores carbonless analogues of GHK peptide, suggesting stronger copper binding and broader conformational flexibility. Learn what this means.
By Peptide Association Research Team
New research on carbonless amino acids reveals modified GHK peptides may have stronger metal binding properties. Study findings and clinical implications.
By Peptide Association Research Team